CN105820088A - N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide new compound and preparation method and application thereof - Google Patents
N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide new compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN105820088A CN105820088A CN201510001329.4A CN201510001329A CN105820088A CN 105820088 A CN105820088 A CN 105820088A CN 201510001329 A CN201510001329 A CN 201510001329A CN 105820088 A CN105820088 A CN 105820088A
- Authority
- CN
- China
- Prior art keywords
- compound
- reactions steps
- solvent
- diethoxy
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a new compound. The name of the compound is N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide; molecular weight of the compound is 649.5; and structure of the compound is as shown in the structural formula (compound 1). Meanwhile, the invention provides a preparation method of the compound 1. The compound provided by the invention has good drug-likeness and can be used in the research field of new drugs, especially in the research field of type-II diabetes innovative drugs.
Description
Technical field
It is a kind of that the present invention relates to offer: the bromo-phenyl of N-(4-)-5-[3-(2; 5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups]-2-ethoxy benzamide noval chemical compound, preparation method and the purposes in innovation drug research thereof; this compound molecular weight is little; novel structure; stable in properties; simple in construction, it is adaptable to innovation drug research is developed, and belongs to technical field of chemistry.
Background technology
Carbamide compounds () when being combined with drug target molecule (macromole such as protein, enzyme) active pocket, owing to the hydrogen atom on nitrogen-atoms in urea groups structure is can critical amino acid residues is combined in drug target molecular activity pocket good hydrogen-bond donor, and carbonyl is the good hydrogen bond receptor that critical amino acid residues is combined in drug target molecular activity pocket in its urea groups, therefore in the compound design of innovation drug research, such group is good dominant group.Compound N-(the bromo-phenyl of 4-)-5-[3-(2; 5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups]-2-ethoxy benzamide is the carbamide compounds containing urea groups structure; this compound structure is novel; stable in properties; simple in construction; in the docking research of Computer-Aided Drug Design, find that this compound can have preferably combination with the drug target of some type ii diabetes, there is certain innovation drug research DEVELOPMENT PROSPECT.
Summary of the invention
1, a kind of noval chemical compound; it is characterized in that; the bromo-phenyl of entitled N-(4-of this compound)-5-[3-(2; 5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups]-2-ethoxy benzamide (compound 1); the molecular weight of this compound is 649.5, and the structural formula of this compound is shown in following formula: compound 1.
2, one prepares the bromo-phenyl of noval chemical compound N-(4-)-5-[3-(2; 5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups] method of-2-ethoxy benzamide; it is characterized in that; including reactions steps g6 shown in following reaction scheme 1, reactions steps g7, reactions steps g8, reactions steps g, reactions steps h, following totally 6 reactions steps of reactions steps i, the condition flag that wherein reactions steps g, reactions steps h, this 3 step of reactions steps i are reacted is as follows:
The condition of reactions steps g is: 2,5-diethoxy-4-Nitro-benzyl amine and compound G molar ratio range are 0.8:1 ~ 1.3:1, triethylamine and compound G mol ratio=0.8:1 ~ 5:1), solvent is N, N dimethylformamide or dimethyl sulfoxide or single solvent or the combination of solvent such as acetone or Isosorbide-5-Nitrae dioxane, reaction temperature is 50 ~ 120 degree, response time is 5 ~ 18 hours, and reaction is purified to obtain product compound H, yield spectra 50% ~ 90% through concentrate, extract, crystallization etc. after terminating；The condition of reactions steps h is: Nickel dichloride hexahydrate and compound H molar ratio range are 0.9:1 ~ 2.5:1, sodium borohydride and compound H molar ratio range are 0.9:1 ~ 4:1, solvent is dichloromethane or the single solvent such as oxolane or ether or the combination of solvent, response time is 10 minutes ~ 12 hours, reaction is purified to obtain product compound I, yield spectra 50% ~ 95% through extraction, crystallization etc. after terminating；The condition of reactions steps i is: alkyl sulfonyl chloride and compound I molar ratio range are 0.8:1 ~ 1.5:1, pyridine and compound I molar ratio range are 0.9:1 ~ 1:1.5:1, solvent is dichloromethane or oxolane or ether or N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, reaction temperature is 0 ~ 80 degree, 3 ~ 18 hours response time, reaction is purified to obtain product compound 1, yield spectra 50% ~ 95% through extraction, crystallization, column chromatography etc. after terminating.
3, the compound that the present invention provides has good quasi-medicated property, can be used for new drug research field and especially treats type ii diabetes field of innovative medicine research.
4, a kind of pharmaceutical composition, including the compound described in the claim 1 of therapeutically effective amount or its pharmaceutically acceptable salt.
5, according to claim 4 requiring compositions, it is characterized in that, this pharmaceutical composition contains one or more pharmaceutically acceptable carrier or excipient further.
6, pharmaceutical composition according to claim 4, is characterized in that, described compound or its pharmaceutically acceptable salt account for gross weight ratio 50% ~ 99.5% as active component.
Below in conjunction with specific embodiment, the present invention is further elaborated, but is not intended to the present invention.
Specific embodiment
The bromo-phenyl of embodiment 1::N-(4-) structural formula of-5-[3-(2,5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups]-2-ethoxy benzamide (compound 1) is as follows:
The bromo-phenyl of compound: N-(4-) synthetic route of-5-[3-(2,5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups]-2-ethoxy benzamide is as follows:
nullThe bromo-phenyl of compound: N-(4-)-5-[3-(2,5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups] the concrete preparation method of-2-ethoxy benzamide is as follows: the preparation of reactions steps g6(compound G1-6): by 2-ethyoxyl-5-nitro-benzoyl chloride (500mg，2.18mmol) add in 100ml eggplant type bottle，Add dichloromethane to be completely dissolved，Add para-bromoaniline (375mg，2.18mmol)，Add triethylamine (242mg，2.40mmol)，Room temperature reaction 0.5-2h，Reaction terminates to wash three times with the hydrochloric acid solution of 10%，It is concentrated under reduced pressure to give crude product，Use column chromatography sharp separation，Use dichloromethane eluent，Obtain the bromo-phenyl of sterling N-(4-)-2-ethyoxyl-5-nitro-benzamide (500mg，62.9%)；nullThe preparation of reactions steps g7(compound G1-7): by bromo-for N-(4-phenyl)-2-ethyoxyl-5-nitro-benzamide (470mg，1.29mmol) add in 100ml eggplant type bottle and add methanol，Add Nickel dichloride hexahydrate (525mg，2.2mmol)，After being completely dissolved，Add sodium borohydride (168mg，4.4mmol)，React 5-10 minute，Reaction carries out concentrating under reduced pressure after terminating，Add the hydrochloric acid solution of 10%，Wash three times by ethyl acetate，Obtain aqueous phase，Add ammonia regulation PH > 11，Wash 3 times by ethyl acetate，Obtain organic facies，Concentrating under reduced pressure i.e. can get crude product，Separate by column chromatography，The methylene chloride/methanol of 100:1 is eluant，Obtain the sterling 5-bromo-phenyl of amino-N-(4-)-2-ethyoxyl-Benzoylamide (380mg，88.0%)；The preparation of reactions steps g8(compound G1-8): by phenyl chloroformate (156.5mg, 1.0mmol) add in the eggplant type bottle of 100ml, add dichloromethane, add the 5-bromo-phenyl of amino-N-(4-)-2-ethyoxyl-Benzoylamide (335mg, 1.0mmol) with triethylamine (111mg, 1.1mmol), room temperature reaction 0.5-2h, reaction is washed 3 times with the hydrochloric acid solution of 10% after terminating, it is concentrated under reduced pressure to give crude product, carry out recrystallization with ethanol and can get sterling [the bromo-phenylcarbamoyl of 3-(4-)-4-ethoxyl phenenyl]-phenyl carbamate (420mg, productivity 92.3%)；The preparation of reactions steps g(compound H): by 2, 5-diethoxy-4-Nitro-benzyl amine (211mg, 0.879mmol), [the bromo-phenylcarbamoyl of 3-(4-)-4-ethoxyl phenenyl]-phenyl carbamate (400mg, 0.879mmol) with triethylamine (0.97g, 8.79mmol) add in the eggplant type bottle of 100ml, add dioxanes, it is heated to 60-80 DEG C, reaction is overnight, reaction is concentrated under reduced pressure to give crude product after terminating, recrystallization is carried out with methanol, obtain the bromo-phenyl of sterling N-(4-)-5-[3-(2, 5-diethoxy-4-Nitro-benzyl)-urea groups]-2-ethyoxyl-Benzoylamide (400mg, productivity 75.8%)；nullThe preparation of reactions steps h(compound I): by bromo-for N-(4-phenyl)-5-[3-(2,5-diethoxy-4-Nitro-benzyl)-urea groups]-2-ethyoxyl-Benzoylamide (380mg,0.63mmol) add in the eggplant type bottle of 100ml，Add methanol，Add Nickel dichloride hexahydrate (258mg，1.08mmol)，After being completely dissolved，Add sodium borohydride (82.4mg，2.17mmol)，Room temperature reaction 5-10 minute，Reaction carries out concentrating under reduced pressure after terminating，Add the hydrochloric acid solution of 10%，Wash three times by ethyl acetate，Obtain aqueous phase，Add ammonia regulation PH > 11，Wash 3 times by ethyl acetate，Obtain organic facies，Concentrating under reduced pressure i.e. can get crude product，Separate by column chromatography，The methylene chloride/methanol of 100:1 is eluant，Obtain sterling 5-[3-(4-amino-2,5-diethoxy-benzyl)-urea groups] the bromo-phenyl of-N-(4-)-2-ethyoxyl-Benzoylamide (290mg，80.6%)；nullThe preparation of reactions steps i(compound 1): by 5-[3-(4-amino-2,5-diethoxy-benzyl)-urea groups] the bromo-phenyl of-N-(4-)-2-ethyoxyl-Benzoylamide (250mg，0.44mmol) add in the eggplant type bottle of 100ml，Add dichloromethane，Add pyridine (38.2mg，0.48mmol)，Carry out nitrogen protection，Add methylsufonyl chloride (50.4mg，0.44mmol)，Room temperature reaction is overnight，After reaction terminates，Hydrochloric acid solution with 10% washs three times，Obtain organic facies，Concentrating under reduced pressure i.e. can get crude product，Separate by column chromatography，The methylene chloride/methanol of 100:1 is eluant，Obtain the bromo-phenyl of sterling N-(4-)-5-[3-(2,5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups]-2-ethoxy benzamide (120mg，41.9%).1HNMR(400MHz,DMSO)δ10.27(s,1H),8.09(s,1H),7.68(d,J=2.4Hz,1H),7.61–7.51(m,2H),7.34–7.25(m,2H),7.06(d,J=9.2Hz,1H),6.95(s,1H),6.87(s,1H),6.33(t,J=5.8Hz,1H),4.22(d,J=5.6Hz,2H),4.11(q,J=6.8Hz,2H),3.99(m,4H),2.93(s,3H),1.34(m,9H)。
Claims (6)
1. a noval chemical compound; it is characterized in that; the bromo-phenyl of entitled N-(4-of this compound)-5-[3-(2; 5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups]-2-ethoxy benzamide (compound 1); the molecular weight of this compound is 649.5, and the structural formula of this compound is shown in following formula: compound 1.
2. prepare the bromo-phenyl of noval chemical compound N-(4-for one kind)-5-[3-(2; 5-diethoxy-4-Methanesulfonyl-benzYl)-urea groups] method of-2-ethoxy benzamide; it is characterized in that; including reactions steps g6 shown in following reaction scheme 1, reactions steps g7, reactions steps g8, reactions steps g, reactions steps h, following totally 6 reactions steps of reactions steps i, the condition flag that wherein reactions steps g, reactions steps h, this 3 step of reactions steps i are reacted is as follows:
The condition of reactions steps g is: 2,5-diethoxy-4-Nitro-benzyl amine and compound G molar ratio range are 0.8:1 ~ 1.3:1, triethylamine and compound G mol ratio=0.8:1 ~ 5:1), solvent is N, N dimethylformamide or dimethyl sulfoxide or single solvent or the combination of solvent such as acetone or Isosorbide-5-Nitrae dioxane, reaction temperature is 50 ~ 120 degree, response time is 5 ~ 18 hours, and reaction is purified to obtain product compound H, yield spectra 50% ~ 90% through concentrate, extract, crystallization etc. after terminating；The condition of reactions steps h is: Nickel dichloride hexahydrate and compound H molar ratio range are 0.9:1 ~ 2.5:1, sodium borohydride and compound H molar ratio range are 0.9:1 ~ 4:1, solvent is dichloromethane or the single solvent such as oxolane or ether or the combination of solvent, response time is 10 minutes ~ 12 hours, reaction is purified to obtain product compound I, yield spectra 50% ~ 95% through extraction, crystallization etc. after terminating；The condition of reactions steps i is: alkyl sulfonyl chloride and compound I molar ratio range are 0.8:1 ~ 1.5:1, pyridine and compound I molar ratio range are 0.9:1 ~ 1.5:1, solvent is dichloromethane or oxolane or ether or N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, reaction temperature is 0 ~ 80 degree, 3 ~ 18 hours response time, reaction is purified to obtain product compound 1, yield spectra 50% ~ 95% through extraction, crystallization or column chromatography etc. after terminating.
3. the compound that the present invention provides has preferable quasi-medicated property, can be used for new drug research field and especially treats type ii diabetes field of innovative medicine research.
4. a pharmaceutical composition, including the compound described in the claim 1 of therapeutically effective amount or its pharmaceutically acceptable salt.
Pharmaceutical composition the most according to claim 4, is characterized in that, this pharmaceutical composition contains one or more pharmaceutically acceptable carrier or excipient further.
Pharmaceutical composition the most according to claim 4, is characterized in that, described compound or its pharmaceutically acceptable salt account for gross weight ratio 50% ~ 99.5% as active component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510001329.4A CN105820088A (en) | 2015-01-05 | 2015-01-05 | N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide new compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510001329.4A CN105820088A (en) | 2015-01-05 | 2015-01-05 | N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide new compound and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105820088A true CN105820088A (en) | 2016-08-03 |
Family
ID=56986846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510001329.4A Pending CN105820088A (en) | 2015-01-05 | 2015-01-05 | N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide new compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105820088A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106167456A (en) * | 2015-05-20 | 2016-11-30 | 齐鲁工业大学 | New Type Urea albuminoid tyrosine-phosphatase 1B inhibitor and preparation method thereof, pharmaceutical composition and purposes |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418191A (en) * | 2000-08-21 | 2003-05-14 | 株式会社太平洋 | Novel thiourea derivatives and the pharmaceutical compositions containing thd same |
| US20040259912A1 (en) * | 2001-09-28 | 2004-12-23 | Takahiro Matsumoto | Benzine derivatives, process for preparing the same and use thereof |
| CN1852891A (en) * | 2003-07-02 | 2006-10-25 | 格吕伦塔尔有限公司 | Cn1852891 |
| CN101142174A (en) * | 2005-03-19 | 2008-03-12 | 株式会社Amorepacific | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same |
| CN101516361A (en) * | 2006-09-28 | 2009-08-26 | 亚瑞特医疗公司 | Soluble epoxide hydrolase inhibitors |
| WO2010146236A1 (en) * | 2009-06-16 | 2010-12-23 | Biotie Therapies Corp. | Urea substituted sulphonamide derivatives |
-
2015
- 2015-01-05 CN CN201510001329.4A patent/CN105820088A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418191A (en) * | 2000-08-21 | 2003-05-14 | 株式会社太平洋 | Novel thiourea derivatives and the pharmaceutical compositions containing thd same |
| US20040259912A1 (en) * | 2001-09-28 | 2004-12-23 | Takahiro Matsumoto | Benzine derivatives, process for preparing the same and use thereof |
| CN1852891A (en) * | 2003-07-02 | 2006-10-25 | 格吕伦塔尔有限公司 | Cn1852891 |
| CN101142174A (en) * | 2005-03-19 | 2008-03-12 | 株式会社Amorepacific | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same |
| CN101163670A (en) * | 2005-03-19 | 2008-04-16 | 株式会社太平洋 | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same |
| CN101516361A (en) * | 2006-09-28 | 2009-08-26 | 亚瑞特医疗公司 | Soluble epoxide hydrolase inhibitors |
| WO2010146236A1 (en) * | 2009-06-16 | 2010-12-23 | Biotie Therapies Corp. | Urea substituted sulphonamide derivatives |
Non-Patent Citations (1)
| Title |
|---|
| CAO RUIKAIET AL.: ""Oligoamide Duplexes as Organogelators"", 《ORGANIC LETTERS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106167456A (en) * | 2015-05-20 | 2016-11-30 | 齐鲁工业大学 | New Type Urea albuminoid tyrosine-phosphatase 1B inhibitor and preparation method thereof, pharmaceutical composition and purposes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7374496B2 (en) | N-benzenesulfonylbenzamide compounds, compositions and uses thereof for inhibiting Bcl-2 protein | |
| CN101497601B (en) | Process for synthesizing imatinib | |
| CN105820093A (en) | N-benzyl-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethyoxyl benzamide new compound and preparation method and application thereof | |
| CN105820094A (en) | 4-methoxy-benzyl-based substituted benzamide new compound, preparation method and application | |
| CN103880822B (en) | Containing 2,4,6-trisubstituted pyrimidine compounds of 1,2,3-triazole, preparation method and application thereof | |
| CN105820067A (en) | N-{[2,5-diethoxy-4-[(3-phenyl-ureido)-methyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| Ran et al. | A novel route to unsymmetrical disubstituted ureas and thioureas by HMPA catalyzed reductive alkylation with trichlorosilane | |
| CN105820087A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-p-methylphenyl-benzamide new compound and preparation method and application thereof | |
| CN105820090A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-(3-methoxy-phenyl)-benzamide new compound and preparation method and application thereof | |
| CN105820083A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-phenyl-benzamide new compound and preparation method and application thereof | |
| CN105820088A (en) | N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide new compound and preparation method and application thereof | |
| CN105820082A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-isopropyl-benzamide new compound and preparation method and application thereof | |
| CN105820071A (en) | N-{4-[3-(4-bromo-phenyl)-ureidomethyl]-2,5-diethoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820077A (en) | 2-butoxyl-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-methyl benzoate new compound and preparation method and application thereof | |
| CN105820078A (en) | 2-benzyloxy-5-[3-(2,5-diethoxy-4-methanesulfonyl-benzyl)-ureido]- methyl benzoate new compound and preparation method and application thereof | |
| CN105820085A (en) | Ethanesulfonic acid{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-diethoxy-phenyl}-amide new compound, preparation method and application | |
| CN105820080A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-ethyl-benzamide new compound and preparation method and application thereof | |
| CN105820066A (en) | 3-methoxy-benzyl-based substituted benzamide new compound, preparation method and application | |
| CN105820073A (en) | N-{[2,5-diethoxy-4-[(3-phenyl-ureido)-methyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820114A (en) | 6-methyl-pyridine-2-yl-based substituted benzamide new compound, preparation and application | |
| CN105820140A (en) | 3-(morpholine-4-carbonyl)phenyl-based substituted methanesulfonamide new compound, preparation and application | |
| CN105820081A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-propyl-benzamide new compound and preparation method and application thereof | |
| CN105820139A (en) | 3-(pyrrolidine-1-carbonyl)-phenyl-based substituted methanesulfonamide new compound and preparation and application | |
| CN103304535B (en) | Azide and preparation method thereof | |
| CN105820069A (en) | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |
|
| RJ01 | Rejection of invention patent application after publication |